Eric Fain Purchases 20,000 Shares of Orchestra BioMed (NASDAQ:OBIO) Stock

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Director Eric Fain bought 20,000 shares of the business’s stock in a transaction on Thursday, May 14th. The stock was bought at an average cost of $4.13 per share, with a total value of $82,600.00. Following the transaction, the director owned 91,709 shares in the company, valued at $378,758.17. This trade represents a 27.89% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Orchestra BioMed Stock Performance

NASDAQ:OBIO opened at $3.72 on Monday. Orchestra BioMed Holdings, Inc. has a 12 month low of $2.20 and a 12 month high of $5.42. The company has a 50 day simple moving average of $4.29 and a two-hundred day simple moving average of $4.27. The company has a current ratio of 7.03, a quick ratio of 7.01 and a debt-to-equity ratio of 0.35. The company has a market cap of $222.76 million, a PE ratio of -3.84 and a beta of 0.52.

Orchestra BioMed (NASDAQ:OBIO) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.07. Orchestra BioMed had a negative net margin of 166.96% and a negative return on equity of 157.46%. The firm had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.92 million. Research analysts forecast that Orchestra BioMed Holdings, Inc. will post -1.62 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Orchestra BioMed by 28.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company’s stock worth $3,675,000 after buying an additional 324,558 shares during the period. Alyeska Investment Group L.P. bought a new position in shares of Orchestra BioMed during the 3rd quarter valued at about $3,386,000. Pathstone Holdings LLC bought a new position in shares of Orchestra BioMed during the 3rd quarter valued at about $2,495,000. Geode Capital Management LLC boosted its holdings in shares of Orchestra BioMed by 22.4% during the 4th quarter. Geode Capital Management LLC now owns 473,363 shares of the company’s stock valued at $1,965,000 after purchasing an additional 86,564 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Orchestra BioMed by 46.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 263,788 shares of the company’s stock valued at $1,095,000 after purchasing an additional 83,349 shares during the last quarter. Institutional investors own 53.20% of the company’s stock.

Analysts Set New Price Targets

OBIO has been the subject of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Orchestra BioMed in a research report on Thursday. Chardan Capital reissued a “buy” rating and set a $20.00 price objective on shares of Orchestra BioMed in a research report on Thursday, March 12th. Wall Street Zen downgraded shares of Orchestra BioMed from a “hold” rating to a “sell” rating in a research report on Saturday. Barclays boosted their price objective on shares of Orchestra BioMed from $12.00 to $13.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Weiss Ratings downgraded shares of Orchestra BioMed from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, April 21st. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $14.50.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.